Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs f
| Current Price | ₹88.33 |
|---|---|
| Market Cap | ₹141 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 22.4 |
| Return on Equity | 7.92% |
| 52-Week Range | ₹60.00 – ₹111.18 |
| Beta (1Y) | 1.02 |
| Dividend Yield | 1.36% |
1. Pharmaceuticals-100%
Bal Pharma Ltd. is trading at ₹88.33, with a market capitalisation of ₹141 Cr.
Bal Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Bal Pharma Ltd. has a P/E of 22.4 and a return on equity of 7.92%.